RECIPIENT NAME

MALAYAN KRAIT ANTIVENIN TO NEUTRALIZE 0.4

MG/ML OF BUNGARUS CANDIDUS SNAKE VENOM

Malayan Krait Antivenin to Neutralize 0.4 mg/ml of

Bungarus Candidus Snake Venom

The Red Cross produces 7 kinds of Monovalent snake

antivenin that separate into 2 major group that are snake
antivenin against the neurotoxic snake (King cobra
antivenin, Cobra antivenin, Banded Krait antivenin and
Malayan Krait antivenin) and hematotoxic snake (Malayan
pit viper antivenin, Green pit viper antivenin and Russell’s
viper antivenin). The polyvalent snake antivenom are also
produced against such 2 group of snake.

Administration

The freeze-dried antivenin must be reconstituted with the

solution supplied (or 10 ml of sterile water for injection)
prior to the administration.

Dosage of neurotoxic snake antivenin Malayan Krait

antivenom

Initial dose 50 ml. The reconstituted antivenin should be

given by slow intravenous infusion (approx. 2 ml/min).
Subsequent dose can be given every 12 hours according to
the clinical symptoms.

Contraindication

None, unless the patient is known to be hypersensitive to

constitutions of the product, appropriate precautions must
be taken.

Side effects

Occasionally, transient tenderness at the injection site,

cutaneous reaction and alterations in temperature may
occur. In some cases nausea, vomiting and also circulatory
reactions (e.g. tachycardia, bradycardia, hypotension,
sweating, vertigo) and allergic reactions (e.g. with flush,
urticaria, dyspnea) have been observed, extending in
isolated cases as far as shock. Therefore, the patient
should be monitored for an extended period of
time.Therapeutic measures depend on the nature and
severity of side effects. Antihistamines, if necessary
adrenaline, high doses of corticosteroids, volume
replacement, oxygen.

Special precautions

1
 In cases of Malayan Krait snake bites respiratory support
may be essential. Since the antivenin is prepared from
horse serum, sensitization to heterologous protein may
occur in some individuals. To avoid serious allergic
reactions, skin test should be performed prior to the
administration by injection of 0.02 ml of 1:100 antivenin
dilution intradermally. It should be noted that the skin test
may not predict the anaphylaxis nor delay serum sickness
reactions.

Storage and stability

Keep in tightly closed container and store below 25-degree

Celsius. The product shall have a shelf life of 5 years from
the manufacturing date.

The manufacturing plant of QSMI has developed to meet

the GMP requirement and get the GMP certificated from
Thai FDA since 2003.

RECIPIENT NAME
MALAYAN PIT VIPER ANTIVENIN TO NEUTRALIZE
1.6 MG/ML OF CALLOSELASMA RHODOSTOMA
SNAKE VENOM

Malayan Pit Viper Antivenin to Neutralize 1.6 mg/ml

of Calloselasma Rhodostoma Snake Venomthis

The Red Cross produces 7 kinds of Monovalent snake

antivenin that separate into 2 major group that are snake
antivenin against the neurotoxic snake (King cobra
antivenin, Cobra antivenin, Banded Krait antivenin and
Malayan Krait antivenin) and hematotoxic snake (Malayan
pit viper antivenin, Green pit viper antivenin and Russell’s
viper antivenin). The polyvalent snake antivenom are also
produced against such 2 group of snake.

Administration

The freeze-dried antivenin must be reconstituted with the

solution supplied (or 10 ml of sterile water for injection)
prior to the administration.

Dosage of hematoxic snake antivenin Malayan Pit

Viper antivenom

2
 Initial dose of this hematotoxic snake antivenin is 30 ml of
reconstituted antivenin that should be given by slow
intravenous infusion (approx. 2 ml/min). Subsequent dose
can be given every 6 hours according to the clinical
symptoms.

Contraindication

None, unless the patient is known to be hypersensitive to

constitutions of the product, appropriate precautions must
be taken.

Side effects

Occasionally, transient tenderness at the injection site,

cutaneous reaction and alterations in temperature may
occur. In some cases nausea, vomiting and also circulatory
reactions (e.g. tachycardia, bradycardia, hypotension,
sweating, vertigo) and allergic reactions (e.g. with flush,
urticaria, dyspnea) have been observed, extending in
isolated cases as far as shock. Therefore, the patient
should be monitored for an extended period of
time.Therapeutic measures depend on the nature and
severity of side effects. Antihistamines, if necessary
adrenaline, high doses of corticosteroids, volume
replacement, oxygen.

Special precautions

Since the antivenin is prepared from horse serum,

sensitization to heterologous protein may occur in some
individuals. To avoid serious allergic reactions, skin test
should be performed prior to the administration by
injection of 0.02 ml of 1:100 antivenin dilution
intradermally. It should be noted that the skin test may
not predict the anaphylaxis nor delay serum sickness
reactions.

Storage and stability

Keep in tightly closed container and store below 25-degree

Celsius. The product shall have a shelf life of 5 years from
the manufacturing date.

The manufacturing plant of QSMI has developed to meet

the GMP requirement and get the GMP certificated from
Thai FDA since 2003.

3
 RECIPIENT NAME
GREEN PIT VIPER ANTIVENIN TO NEUTRALIZE 0.7
MG/ML OF TRIMERESURUS ALBOLABRIS SNAKE
VENOM

Green Pit Viper Antivenin to Neutralize 0.7 mg/ml of

Trimeresurus Albolabris Snake Venom

The Red Cross produces 7 kinds of Monovalent snake

antivenin that separate into 2 major group that are snake
antivenin against the neurotoxic snake (King cobra
antivenin, Cobra antivenin, Banded Krait antivenin and
Malayan Krait antivenin) and hematotoxic snake (Malayan
pit viper antivenin, Green pit viper antivenin and Russell’s
viper antivenin). The polyvalent snake antivenom are also
produced against such 2 group of snake

Administration

The freeze-dried antivenin must be reconstituted with the

solution supplied (or 10 ml of sterile water for injection)
prior to the administration.

Dosage of hematoxic snake antivenin Green Pit Viper

antivenom

The initial dose of this hematotoxic snake antivenin is 30

ml of reconstituted antivenin that should be given by slow
intravenous infusion (approx. 2 ml/min). Subsequent dose
can be given every 6 hours according to the clinical
symptoms.

Contraindication

None, unless the patient is known to be hypersensitive to

constitutions of the product, appropriate precautions must
be taken.

Side effects

Occasionally, transient tenderness at the injection site,

cutaneous reaction and alterations in temperature may
occur. In some cases nausea, vomiting and also circulatory
reactions (e.g. tachycardia, bradycardia, hypotension,
sweating, vertigo) and allergic reactions (e.g. with flush,
urticaria, dyspnea) have been observed, extending in
isolated cases as far as shock. Therefore, the patient
should be monitored for an extended period of
time.Therapeutic measures depend on the nature and
severity of side effects. Antihistamines, if necessary
adrenaline, high doses of corticosteroids, volume
replacement, oxygen.

4
 Special precautions

Since the antivenin is prepared from horse serum,

sensitization to heterologous protein may occur in some
individuals. To avoid serious allergic reactions, skin test
should be performed prior to the administration by
injection of 0.02 ml of 1:100 antivenin dilution
intradermally. It should be noted that the skin test may
not predict the anaphylaxis nor delay serum sickness
reactions.

Storage and stability

Keep in tightly closed container and store below 25-degree

Celsius. The product shall have a shelf life of 5 years from
the manufacturing date.

The manufacturing plant of QSMI has developed to meet

the GMP requirement and get the GMP certificated from
Thai FDA since 2003.

RECIPIENT NAME
COBRA ANTIVENIN TO NEUTRALIZE 0.6 MG/ML OF
NAJA KAOUTHIA SNAKE VENOM

Cobra Antivenin to Neutralize 0.8 mg/ml of Naja

Kaouthia Snake Venom

The Red Cross produces 7 kinds of Monovalent snake

antivenin that separate into 2 major group that are snake
antivenin against the neurotoxic snake (King cobra
antivenin, Cobra antivenin, Banded Krait antivenin and
Malayan Krait antivenin) and hematotoxic snake (Malayan
pit viper antivenin, Green pit viper antivenin and Russell’s
viper antivenin). The polyvalent snake antivenom are also
produced against such 2 group of snake.

Administration

The freeze-dried antivenin must be reconstituted with the

solution supplied (or 10 ml of sterile water for injection)
prior to the administration.

Dosage of neurotoxic snake antivenin Cobra

5
 antivenom

Initial dose 100 ml. The reconstituted antivenin should be

given by slow intravenous infusion (approx. 2 ml/min).
Subsequent dose can be given every 12 hours according to
the clinical symptoms.

Contraindication

None, unless the patient is known to be hypersensitive to

constitutions of the product, appropriate precautions must
be taken.

Side effects

Occasionally, transient tenderness at the injection site,

cutaneous reaction and alterations in temperature may
occur. In some cases nausea, vomiting and also circulatory
reactions (e.g. tachycardia, bradycardia, hypotension,
sweating, vertigo) and allergic reactions (e.g. with flush,
urticaria, dyspnea) have been observed, extending in
isolated cases as far as shock. Therefore, the patient
should be monitored for an extended period of
time.Therapeutic measures depend on the nature and
severity of side effects. Antihistamines, if necessary
adrenaline, high doses of corticosteroids, volume
replacement, oxygen.

Special precautions

In cases of Cobra respiratory support may be essential.

Since the antivenin is prepared from horse serum,
sensitization to heterologous protein may occur in some
individuals. To avoid serious allergic reactions, skin test
should be performed prior to the administration by
injection of 0.02 ml of 1:100 antivenin dilution
intradermally. It should be noted that the skin test may
not predict the anaphylaxis nor delay serum sickness
reactions.

Storage and stability

Keep in tightly closed container and store below 25-degree

Celsius. The product shall have a shelf life of 5 years from
the manufacturing date.

The manufacturing plant of QSMI has developed to meet

the GMP requirement and get the GMP certificated from
Thai FDA since 2003.

6
 RECIPIENT NAME
KING COBRA ANTIVENIN TO NEUTRALIZE 0.8
MG/ML OF OPHIOPHAGUS HANNAH SNAKE VENOM

King Cobra Antivenin to Neutralize 0.8 mg/ml of

Ophiophagus Hannah Snake Venom

The Red Cross produces 7 kinds of Monovalent snake

antivenin that separate into 2 major group that are snake
antivenin against the neurotoxic snake (King cobra
antivenin, Cobra antivenin, Banded Krait antivenin and
Malayan Krait antivenin) and hematotoxic snake (Malayan
pit viper antivenin, Green pit viper antivenin and Russell’s
viper antivenin). The polyvalent snake antivenom are also
produced against such 2 group of snake.

Administration

The freeze-dried antivenin must be reconstituted with the

solution supplied (or 10 ml of sterile water for injection)
prior to the administration.

Dosage of Neurotoxic snake antivenin King Cobra

antivenom

Initial dose 100 ml. The reconstituted antivenin should be

given by slow intravenous infusion (approx. 2 ml/min).
Subsequent dose can be given every 12 hours according to
the clinical symptoms.

Contraindication

None, unless the patient is known to be hypersensitive to

constitutions of the product, appropriate precautions must
be taken.

Side effects

Occasionally, transient tenderness at the injection site,

cutaneous reaction and alterations in temperature may
occur. In some cases nausea, vomiting and also circulatory
reactions (e.g. tachycardia, bradycardia, hypotension,
sweating, vertigo) and allergic reactions (e.g. with flush,
urticaria, dyspnea) have been observed, extending in
isolated cases as far as shock. Therefore, the patient
should be monitored for an extended period of
time.Therapeutic measures depend on the nature and
severity of side effects. Antihistamines, if necessary
adrenaline, high doses of corticosteroids, volume
replacement, oxygen.

Special precautions

7
 In cases of Cobra respiratory support may be essential.
Since the antivenin is prepared from horse serum,
sensitization to heterologous protein may occur in some
individuals. To avoid serious allergic reactions, skin test
should be performed prior to the administration by
injection of 0.02 ml of 1:100 antivenin dilution
intradermally. It should be noted that the skin test may
not predict the anaphylaxis nor delay serum sickness
reactions.

Storage and stability

Keep in tightly closed container and store below 25-degree

Celsius. The product shall have a shelf life of 5 years from
the manufacturing date.

The manufacturing plant of QSMI has developed to meet

the GMP requirement and get the GMP certificated from
Thai FDA since 2003.

RECIPIENT NAME
RUSSELL’S VIPER ANTIVENIN TO NEUTRALIZE 0.6
MG/ML OF DABOIA RUSSELLI SIAMENSIS SNAKE
VENOM

Russell’s Viper Antivenin to Neutralize 0.6 mg/ml of

Daboia Russelli Siamensis Snake Venom

The Red Cross produces 7 kinds of Monovalent snake

antivenin that separate into 2 major group that are snake
antivenin against the neurotoxic snake (King cobra
antivenin, Cobra antivenin, Banded Krait antivenin and
Malayan Krait antivenin) and hematotoxic snake (Malayan
pit viper antivenin, Green pit viper antivenin and Russell’s
viper antivenin). The polyvalent snake antivenom are also
produced against such 2 group of snake.

Administration

The freeze-dried antivenin must be reconstituted with the

solution supplied (or 10 ml of sterile water for injection)
prior to the administration.

Dosage of hematoxic snake antivenin Russell’s Viper

8
 antivenom

The initial dose of this hematotoxic snake antivenin is 30

ml of reconstituted antivenin that should be given by slow
intravenous infusion (approx. 2 ml/min). Subsequent dose
can be given every 6 hours according to the clinical
symptoms.

Contraindication

None, unless the patient is known to be hypersensitive to

constitutions of the product, appropriate precautions must
be taken.

Side effects

Occasionally, transient tenderness at the injection site,

cutaneous reaction and alterations in temperature may
occur. In some cases nausea, vomiting and also circulatory
reactions (e.g. tachycardia, bradycardia, hypotension,
sweating, vertigo) and allergic reactions (e.g. with flush,
urticaria, dyspnea) have been observed, extending in
isolated cases as far as shock. Therefore, the patient
should be monitored for an extended period of
time.Therapeutic measures depend on the nature and
severity of side effects. Antihistamines, if necessary
adrenaline, high doses of corticosteroids, volume
replacement, oxygen.

Special precautions

Since the antivenin is prepared from horse serum,

sensitization to heterologous protein may occur in some
individuals. To avoid serious allergic reactions, skin test
should be performed prior to the administration by
injection of 0.02 ml of 1:100 antivenin dilution
intradermally. It should be noted that the skin test may
not predict the anaphylaxis nor delay serum sickness
reactions.

Storage and stability

Keep in tightly closed container and store below 25-degree

Celsius. The product shall have a shelf life of 5 years from
the manufacturing date.

The manufacturing plant of QSMI has developed to meet

the GMP requirement and get the GMP certificated from
Thai FDA since 2003.

9
 RECIPIENT NAME
BANDED KRAIT ANTIVENIN TO NEUTRALIZE 0.6
MG/ML OF BUNGARUS FASCIATUS SNAKE VENOM

Banded Krait Antivenin to Neutralize 0.6 mg/ml of

Bungarus fasciatus Snake Venom

The Red Cross produces 7 kinds of Monovalent snake

antivenin that separate into 2 major group that are snake
antivenin against the neurotoxic snake (King cobra
antivenin, Cobra antivenin, Banded Krait antivenin and
Malayan Krait antivenin) and hematotoxic snake (Malayan
pit viper antivenin, Green pit viper antivenin and Russell’s
viper antivenin). The polyvalent snake antivenom are also
produced against such 2 group of snake.

Administration

The freeze-dried antivenin must be reconstituted with the

solution supplied (or 10 ml of sterile water for injection)
prior to the administration.

Dosage of neurotoxic snake antivenin Banded Krait

antivenom

Initial dose 50 ml. The reconstituted antivenin should be

given by slow intravenous infusion (approx. 2 ml/min).
Subsequent dose can be given every 12 hours according to
the clinical symptoms.

Contraindication

None, unless the patient is known to be hypersensitive to

constitutions of the product, appropriate precautions must
be taken.

Side effects

Occasionally, transient tenderness at the injection site,

cutaneous reaction and alterations in temperature may
occur. In some cases nausea, vomiting and also circulatory
reactions (e.g. tachycardia, bradycardia, hypotension,
sweating, vertigo) and allergic reactions (e.g. with flush,
urticaria, dyspnea) have been observed, extending in
isolated cases as far as shock. Therefore, the patient
should be monitored for an extended period of
time.Therapeutic measures depend on the nature and
severity of side effects. Antihistamines, if necessary
adrenaline, high doses of corticosteroids, volume
replacement, oxygen.

Special precautions

10
 In cases of Krait snake bites respiratory support may be
essential. Since the antivenin is prepared from horse
serum, sensitization to heterologous protein may occur in
some individuals. To avoid serious allergic reactions, skin
test should be performed prior to the administration by
injection of 0.02 ml of 1:100 antivenin dilution
intradermally. It should be noted that the skin test may
not predict the anaphylaxis nor delay serum sickness
reactions.

Storage and stability

Keep in tightly closed container and store below 25-degree

Celsius. The product shall have a shelf life of 5 years from
the manufacturing date.

The manufacturing plant of QSMI has developed to meet

the GMP requirement and get the GMP certificated from
Thai FDA since 2003.

11
 VARIANT OF ANTIVENOM MONOVALENT
MADE IN THAILAND

Reference:
1. Product Leaflet

12